1. Home
  2. EPRT vs ERAS Comparison

EPRT vs ERAS Comparison

Compare EPRT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Essential Properties Realty Trust Inc.

EPRT

Essential Properties Realty Trust Inc.

HOLD

Current Price

$31.50

Market Cap

6.6B

Sector

Real Estate

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$9.97

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPRT
ERAS
Founded
2016
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
5.5B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
EPRT
ERAS
Price
$31.50
$9.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
12
Target Price
$36.79
$14.25
AVG Volume (30 Days)
2.0M
9.3M
Earning Date
04-22-2026
05-08-2026
Dividend Yield
3.98%
N/A
EPS Growth
11.30
36.23
EPS
0.28
N/A
Revenue
$561,219,000.00
N/A
Revenue This Year
$17.12
N/A
Revenue Next Year
$16.27
N/A
P/E Ratio
$112.11
N/A
Revenue Growth
24.82
N/A
52 Week Low
$28.95
$1.06
52 Week High
$34.73
$24.28

Technical Indicators

Market Signals
Indicator
EPRT
ERAS
Relative Strength Index (RSI) 46.80 34.75
Support Level $29.30 $2.07
Resistance Level $31.79 $17.17
Average True Range (ATR) 0.63 1.55
MACD -0.03 -0.85
Stochastic Oscillator 24.40 8.09

Price Performance

Historical Comparison
EPRT
ERAS

About EPRT Essential Properties Realty Trust Inc.

Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: